Identification

Name
Nadolol
Accession Number
DB01203  (APRD00301)
Type
Small Molecule
Groups
Approved
Description

A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem]

Structure
Thumb
Synonyms
  • Nadolol
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CorgardTablet40 mg/1OralBristol-Myers Squibb Company2006-02-162006-02-16Us
CorgardTablet40 mg/1OralPfizer Laboratories Div Pfizer Inc.1979-12-10Not applicableUs
CorgardTablet120 mg/1OralBristol-Myers Squibb Company2006-02-162006-02-16Us
CorgardTablet20 mg/1OralUs World Meds, Llc2016-04-01Not applicableUs
CorgardTablet40 mg/1OralPhysicians Total Care, Inc.1979-12-102012-06-30Us
CorgardTablet80 mg/1OralUs World Meds, Llc2016-04-01Not applicableUs
CorgardTablet80 mg/1OralBristol-Myers Squibb Company2006-02-162006-02-16Us
CorgardTablet80 mg/1OralPfizer Laboratories Div Pfizer Inc.1979-12-10Not applicableUs
CorgardTablet160 mg/1OralBristol-Myers Squibb Company2006-02-162006-02-16Us
CorgardTablet40 mg/1OralUs World Meds, Llc2016-04-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NadololTablet40 mg/1OralSandoz Inc2008-10-01Not applicableUs
NadololTablet20 mg/1OralCipla Limited2016-02-23Not applicableUs
NadololTablet40 mg/1OralMylan Pharmaceuticals Inc.1993-10-31Not applicableUs51079 0813 20 nlmimage10 8c32c646
NadololTablet40 mg/1OralPhysicians Total Care, Inc.2010-01-14Not applicableUs54868 325720180907 15195 voc06i
NadololTablet20 mg/1OralAmerincan Health Packaging2014-04-012014-04-17Us00781 1181 01 nlmimage10 a108d096
NadololTablet80 mg/1OralGreenstone, Llc2014-04-28Not applicableUs59762 0812 01 nlmimage10 b83c5c32
NadololTablet40 mg/1OralCadila Pharnmaceuticals2017-08-08Not applicableUs
NadololTablet20 mg/1OralAmneal Pharmaceuticals2017-06-02Not applicableUs
NadololTablet40 mg/1OralRebel Distributors2008-10-01Not applicableUs
NadololTablet80 mg/1Oralbryant ranch prepack2008-10-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CorzideNadolol (80 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralPfizer Laboratories Div Pfizer Inc.1983-05-25Not applicableUs
CorzideNadolol (80 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralPhysicians Total Care, Inc.1983-05-252010-06-30Us
CorzideNadolol (80 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralMonarch Pharmaceuticals, Inc.2006-10-102006-10-10Us
CorzideNadolol (40 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralPfizer Laboratories Div Pfizer Inc.1983-05-25Not applicableUs
CorzideNadolol (40 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralMonarch Pharmaceuticals, Inc.2006-10-102006-10-10Us
Corzide Tab W Nadolol 40mgNadolol (40 mg) + Bendroflumethiazide (5 mg)TabletOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1987-12-311997-08-14Canada
Corzide Tab W Nadolol 80mgNadolol (80 mg) + Bendroflumethiazide (5 mg)TabletOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1987-12-311997-08-14Canada
Nadolol and BendroflumethiazideNadolol (80 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralImpax Generics2007-03-30Not applicableUs
Nadolol and BendroflumethiazideNadolol (80 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralMylan Pharmaceuticals2012-04-022012-08-31Us
Nadolol and BendroflumethiazideNadolol (40 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralMylan Pharmaceuticals2012-04-022012-08-31Us
International/Other Brands
Anabet / Corgard / Solgol
Categories
UNII
FEN504330V
CAS number
42200-33-9
Weight
Average: 309.4006
Monoisotopic: 309.194008357
Chemical Formula
C17H27NO4
InChI Key
VWPOSFSPZNDTMJ-UCWKZMIHSA-N
InChI
InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1
IUPAC Name
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
SMILES
CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2

Pharmacology

Indication

Used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension.

Associated Conditions
Pharmacodynamics

Nadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.

Mechanism of action

Like other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
Absorption

Absorption of nadolol after oral dosing is variable, averaging about 30 percent.

Volume of distribution
Not Available
Protein binding

30%

Metabolism

Not metabolized by the liver and excreted unchanged primarily by the kidneys.

Route of elimination

Unlike many other beta-adrenergic blocking agents, nadolol is not metabolized by the liver and is excreted unchanged, principally by the kidneys. Nadolol is excreted predominantly in the urine.

Half life

14-24 hours

Clearance
Not Available
Toxicity

Oral, mouse: LD50 = 4500mg/kg. Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nadolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidNadolol may increase the hypotensive activities of 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
1-benzylimidazoleThe risk or severity of hypertension can be increased when Nadolol is combined with 1-benzylimidazole.
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Nadolol.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of hypertension can be increased when Nadolol is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of hypertension can be increased when Nadolol is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of hypertension can be increased when Nadolol is combined with 3,4-Methylenedioxyamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of hypertension can be increased when Nadolol is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Nadolol.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of hypertension can be increased when Nadolol is combined with 5-methoxy-N,N-dimethyltryptamine.
AbacavirAbacavir may decrease the excretion rate of Nadolol which could result in a higher serum level.
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Magnesium, potassium and zinc needs increased.
  • Take without regard to meals.

References

Synthesis Reference
US3935267
General References
Not Available
External Links
Human Metabolome Database
HMDB0015334
KEGG Drug
D00432
PubChem Compound
39147
PubChem Substance
46505509
ChemSpider
35815
BindingDB
25766
ChEBI
7444
ChEMBL
CHEMBL649
Therapeutic Targets Database
DAP000122
PharmGKB
PA450573
IUPHAR
554
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Nadolol
ATC Codes
C07AA12 — NadololC07BA12 — Nadolol and thiazides
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
MSDS
Download (74.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1, 2CompletedTreatmentAsthma Bronchial1
2Active Not RecruitingTreatmentMild Persistent Asthma, Uncomplicated1
2CompletedTreatmentCessation, Smoking1
2CompletedTreatmentInfantile Hemangiomas1
3RecruitingTreatmentInfantile Hemangiomas1
3WithdrawnPreventionHemorrhage, Gastrointestinal / Portal Hypertension1
4CompletedPreventionHemorrhage, Gastrointestinal / Liver Cirrhosis / Portal Hypertension1
4CompletedPreventionLiver Cirrhosis / Variceal Bleeding1
4CompletedPreventionVariceal Rebleeding1
4CompletedTreatmentMigrainous Headache1
4Unknown StatusPreventionGastric Variceal Bleeding / Liver Cirrhosis and Hepatoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Apothecon
  • Cardinal Health
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • E.R. Squibb and Sons LLC
  • Emcure Pharmaceuticals Ltd.
  • Global Pharmaceuticals
  • Impax Laboratories Inc.
  • Ivax Pharmaceuticals
  • King Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Mead Johnson and Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Professional Co.
  • Qualitest
  • Quality Care
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Sandoz
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
Dosage forms
FormRouteStrength
TabletOral120 mg/1
TabletOral
TabletOral160 mg/1
TabletOral160 mg
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
TabletOral40 mg
TabletOral80 mg
Prices
Unit descriptionCostUnit
Nadolol powder94.8USD g
Corgard 160 mg tablet4.4USD tablet
Corgard 80 mg tablet4.33USD tablet
Corgard 120 mg tablet3.96USD tablet
Corgard 40 mg tablet3.11USD tablet
Corgard 20 mg tablet3.04USD tablet
Nadolol 160 mg tablet2.25USD tablet
Nadolol 80 mg tablet1.45USD tablet
Apo-Nadol 160 mg Tablet1.26USD tablet
Nadolol 40 mg tablet1.07USD tablet
Naldol 80 mg tablet1.03USD tablet
Nadolol 20 mg tablet0.92USD tablet
Apo-Nadol 80 mg Tablet0.37USD tablet
Novo-Nadolol 80 mg Tablet0.37USD tablet
Apo-Nadol 40 mg Tablet0.26USD tablet
Novo-Nadolol 40 mg Tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)124-136 °CPhysProp
water solubility8330 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.81SANGSTER (1994)
Caco2 permeability-5.41ADME Research, USCD
pKa9.67MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility2.25 mg/mLALOGPS
logP1.23ALOGPS
logP0.87ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)13.59ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area81.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity85.53 m3·mol-1ChemAxon
Polarizability34.63 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9788
Blood Brain Barrier-0.966
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8317
P-glycoprotein inhibitor IInhibitor0.6192
P-glycoprotein inhibitor IINon-inhibitor0.7842
Renal organic cation transporterNon-inhibitor0.8736
CYP450 2C9 substrateNon-substrate0.7934
CYP450 2D6 substrateSubstrate0.7284
CYP450 3A4 substrateNon-substrate0.5456
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8072
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8934
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.7972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Inhibitor0.5781
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0019000000-fdb4087c676d8d8d4a8e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0092000000-e09452da687c6073a284
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0uk9-4690000000-81baaf08e07647128956
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0kmi-4930000000-adbaba8c066f6c5c5558
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0aba-3900000000-3784678375e682bb5b2f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05te-3900000000-52bc796915dc7eb2ff30
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0ik9-0379000000-d94563052914b6b9e468
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0k92-2920000000-2a6eb574de4bc8d52292

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Tetralins
Sub Class
Not Available
Direct Parent
Tetralins
Alternative Parents
Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Tetralin / Alkyl aryl ether / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Ether / Secondary amine / Organic nitrogen compound / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Wheeldon NM, McDevitt DG, Lipworth BJ: The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1994 Aug;38(2):103-8. [PubMed:7981009]
  3. Koshiji M, Ito H, Minatoguchi S, Watanabe H, Imai Y, Kakami M, Hirakawa S: A comparison of guanfacine, bunazosin, atenolol and nadolol on blood pressure and plasma noradrenaline responses to cold pressor testing. Clin Exp Pharmacol Physiol. 1992 Jul;19(7):481-8. [PubMed:1354084]
  4. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496]
  5. Varma DR: Ligand-independent negative chronotropic responses of rat and mouse right atria to beta-adrenoceptor antagonists. Can J Physiol Pharmacol. 1999 Dec;77(12):943-9. [PubMed:10606440]
  6. Wheeldon NM, McDevitt DG, Lipworth BJ: Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man. Br J Clin Pharmacol. 1994 Apr;37(4):363-9. [PubMed:7912539]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Wheeldon NM, McDevitt DG, Lipworth BJ: The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1994 Aug;38(2):103-8. [PubMed:7981009]
  3. Ozakca I, Arioglu E, Guner S, Altan VM, Ozcelikay AT: Role of beta-3-adrenoceptor in catecholamine-induced relaxations in gastric fundus from control and diabetic rats. Pharmacology. 2007;80(4):227-38. Epub 2007 Jul 6. [PubMed:17622774]
  4. Liu YL, Toubro S, Astrup A, Stock MJ: Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes Relat Metab Disord. 1995 Sep;19(9):678-85. [PubMed:8574280]
  5. Wheeldon NM, McDevitt DG, Lipworth BJ: Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol. Br J Clin Pharmacol. 1992 Apr;33(4):411-6. [PubMed:1349493]
  6. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H: Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. doi: 10.1016/j.dmpk.2016.08.007. Epub 2016 Sep 2. [PubMed:27836712]
  2. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. [PubMed:14732961]
  3. Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A: Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):981-1007. doi: 10.1517/17425255.2.6.981 . [PubMed:17125412]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9. [PubMed:8953513]

Drug created on June 13, 2005 07:24 / Updated on December 14, 2018 17:09